Latest & greatest articles for fluoxetine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluoxetine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluoxetine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluoxetine

21. Fluoxetine

Fluoxetine Drug Approval Package: Fluoxetine hydrochloride NDA #202133 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Fluoxetine 60 mg tablets Company: Edgemont Pharmaceuticals Application No.: 202133 Approval Date: 10/6/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: April 24, 2012 Vision impaired people having

2011 FDA - Drug Approval Package

22. Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials

Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

23. Fluoxetine, trazodone and ritanserin are more effective than placebo when used as add-on therapies for negative symptoms of schizophrenia

Fluoxetine, trazodone and ritanserin are more effective than placebo when used as add-on therapies for negative symptoms of schizophrenia Fluoxetine, trazodone and ritanserin are more effective than placebo when used as add-on therapies for negative symptoms of schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies (...) , please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Fluoxetine, trazodone and ritanserin are more effective than placebo when used as add-on therapies for negative

2011 Evidence-Based Mental Health

24. Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: a meta-analysis Full Text available with Trip Pro

Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: a meta-analysis Depression may affect patients' recovery and even their survival rate after stroke, but it is often overlooked or inadequately managed; data regarding the prophylactic efficacy and safety of fluoxetine are inconsistent in this setting.The objective of the study is to systematically assess the prophylactic efficacy and safety of fluoxetine for poststroke depression in patients with stroke.We searched (...) electronic databases up to December 2009 for studies evaluating the prophylactic efficacy of fluoxetine in patients with stroke. The pooled odds ratio (OR), weighted mean difference (WMD), incremental efficiency and 95% confidence intervals (95% CI) were calculated.We collected and evaluated a total of 385 patients identified from six trials. Meta-analysis demonstrated that fluoxetine reduced the incidence of poststroke depression (PSD) (OR = 0.25, 95% CI 0.11 to 0.56), helped recovery in neurological

2010 EvidenceUpdates

25. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study Full Text available with Trip Pro

Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study The authors examined the safety and efficacy of long-term fluoxetine monotherapy, lithium monotherapy, and placebo therapy in preventing relapse and recurrence of bipolar type II major depressive episode. The authors hypothesized that fluoxetine monotherapy would be superior to lithium monotherapy with a similar hypomanic mood conversion (...) rate.Patients at least 18 years old who recovered from their major depressive episode during initial open-label fluoxetine monotherapy were randomly assigned to receive 50 weeks of double-blind monotherapy with fluoxetine at 10-40 mg/day, lithium at 300-1200 mg/day, or placebo. The primary outcome measure was time to relapse or recurrence. Secondary outcome measures included the proportion of patients remaining well and the frequency of hypomanic symptoms.There were no significant differences in clinical

2010 EvidenceUpdates Controlled trial quality: predicted high

26. Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin

Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about (...) death compared with fluoxetine, citalopram or dosulepin Article Text Aetiology Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin Statistics from Altmetric.com Question Question Is the antidepressant venlafaxine associated with an increased risk of sudden cardiac death compared with other antidepressants? People The cohort consisted of 207 384 new users of venlafaxine, fluoxetine, citalopram or dosulepin

2010 Evidence-Based Mental Health

27. Compared with fluoxetine monotherapy, mirtazapine plus venlafaxine or fluoxetine increase remission but not response in patients with major depressive disorder

Compared with fluoxetine monotherapy, mirtazapine plus venlafaxine or fluoxetine increase remission but not response in patients with major depressive disorder Compared with fluoxetine monotherapy, mirtazapine plus venlafaxine or fluoxetine increase remission but not response in patients with major depressive disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any (...) time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Compared with fluoxetine monotherapy, mirtazapine plus venlafaxine

2010 Evidence-Based Mental Health

28. Fluoxetine: possible small risk of congenital cardiac defects

Fluoxetine: possible small risk of congenital cardiac defects Fluoxetine: possible small risk of congenital cardiac defects - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Fluoxetine: possible small risk of congenital cardiac defects Recent epidemiological evidence suggests a possible small increased risk of congenital cardiac defects in association with fluoxetine in early pregnancy, similar to that seen with paroxetine. There are insufficient data to draw conclusions (...) on whether there is a similar risk for other SSRIs. The potential risks should be considered in the context of the benefits of treatment Published 11 December 2014 From: Therapeutic area: , Article date: March 2010 Fluoxetine (brand leader Prozac) is a commonly used antidepressant belonging to the selective serotonin reuptake inhibitor (SSRI) class of medicines. Depressive symptoms and major depressive disorders occur in pregnant women with prevalence rates ranging from 7% to 20%. Untreated depression

2010 MHRA Drug Safety Update

29. Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK

Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK Lenox-Smith A, Greenstreet L, Burslem K, Knight C Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of venlafaxine versus either generic fluoxetine or generic amitriptyline for the first-line treatment of patients with major depressive disorder. The authors concluded that, despite its relatively high

2009 NHS Economic Evaluation Database.

30. Cognitive behavioural therapy plus fluoxetine offers some safety advantages over fluoxetine alone in adolescents with depression

Cognitive behavioural therapy plus fluoxetine offers some safety advantages over fluoxetine alone in adolescents with depression Cognitive behavioural therapy plus fluoxetine offers some safety advantages over fluoxetine alone in adolescents with depression | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Cognitive behavioural therapy plus fluoxetine offers some safety advantages over fluoxetine alone in adolescents with depression

2008 Evidence-Based Mental Health

31. Combined fluoxetine plus cognitive behavioural therapy is more effective than monotherapy or placebo for adolescents with depression

Combined fluoxetine plus cognitive behavioural therapy is more effective than monotherapy or placebo for adolescents with depression Combined fluoxetine plus cognitive behavioural therapy is more effective than monotherapy or placebo for adolescents with depression | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please (...) see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Combined fluoxetine plus cognitive behavioural therapy is more effective than monotherapy or placebo for adolescents

2008 Evidence-Based Mental Health

32. Combined olanzapine plus fluoxetine modestly improves symptoms of acute bipolar I depression compared to lamotrigine

Combined olanzapine plus fluoxetine modestly improves symptoms of acute bipolar I depression compared to lamotrigine Combined olanzapine plus fluoxetine modestly improves symptoms of acute bipolar I depression compared to lamotrigine | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Combined olanzapine plus fluoxetine modestly improves symptoms of acute bipolar I depression compared to lamotrigine Article Text Therapeutics Combined

2008 Evidence-Based Mental Health

33. Light therapy and fluoxetine similarly effective for improving seasonal affective disorder

Light therapy and fluoxetine similarly effective for improving seasonal affective disorder Light therapy and fluoxetine similarly effective for improving seasonal affective disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Light therapy and fluoxetine similarly effective for improving seasonal affective disorder Article Text Therapeutics Light therapy and fluoxetine similarly effective for improving seasonal affective disorder Statistics

2008 Evidence-Based Mental Health

34. The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation

The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation Kongsakon R, Bunchapattanasakda C Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of escitalopram versus fluoxetine and venlafaxine for the treatment of major depressive disorder. The authors concluded that escitalopram was more

2008 NHS Economic Evaluation Database.

35. Olanzapine plus fluoxetine reduce depressive symptoms faster than either drug alone in people with treatment resistant depression

Olanzapine plus fluoxetine reduce depressive symptoms faster than either drug alone in people with treatment resistant depression Olanzapine plus fluoxetine reduce depressive symptoms faster than either drug alone in people with treatment resistant depression | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Olanzapine plus fluoxetine reduce depressive symptoms faster than either drug alone in people with treatment resistant depression

2007 Evidence-Based Mental Health

36. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. Full Text available with Trip Pro

Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. To compare the risk of suicide in adults using the antidepressant venlafaxine compared with citalopram, fluoxetine, and dothiepin.Retrospective cohort study.UK General Practice Research Database.219,088 patients, aged 18-89 years, who were prescribed venlafaxine, citalopram, fluoxetine, or dothiepin from 1995 to 2005.Completed suicide and attempted suicide.Venlafaxine users had (...) a higher burden of risk factors for suicide, including previous suicide attempts and proxies for severe depression or depression that was difficult to treat. In the analysis for completed suicides, unadjusted and adjusted hazard ratios for venlafaxine compared with citalopram were 2.44 (95% confidence interval 1.12 to 5.31) and 1.70 (0.76 to 3.80), for venlafaxine compared with fluoxetine were 2.85 (1.37 to 5.94) and 1.63 (0.74 to 3.59), and for venlafaxine compared with dothiepin were 2.54 (1.07

2007 BMJ

37. Eye movement desensitisation and reprocessing reduces PTSD symptoms compared with fluoxetine at six months post-treatment

Eye movement desensitisation and reprocessing reduces PTSD symptoms compared with fluoxetine at six months post-treatment Eye movement desensitisation and reprocessing reduces PTSD symptoms compared with fluoxetine at six months post-treatment | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Eye movement desensitisation and reprocessing reduces PTSD symptoms compared with fluoxetine at six months post-treatment Article Text

2007 Evidence-Based Mental Health

38. Continuing fluoxetine treatment may delay relapse in children and adolescents with major depressive disorder Full Text available with Trip Pro

Continuing fluoxetine treatment may delay relapse in children and adolescents with major depressive disorder Continuing fluoxetine treatment may delay relapse in children and adolescents with major depressive disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Continuing fluoxetine treatment may delay relapse in children and adolescents with major depressive disorder Article Text Therapeutics Continuing fluoxetine treatment may delay

2006 Evidence-Based Mental Health

39. Fluoxetine improves minor depressive disorders Full Text available with Trip Pro

Fluoxetine improves minor depressive disorders Fluoxetine improves minor depressive disorders | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Fluoxetine improves minor depressive disorders Article Text Therapeutics Fluoxetine improves minor depressive disorders Free Philip J Cowen , MD, FRCPsych Statistics from Altmetric.com Judd LL, Rapaport MH, Yonkers KA, et al . Randomized, placebo-controlled trial of fluoxetine for acute treatment

2006 Evidence-Based Mental Health

40. Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder Full Text available with Trip Pro

Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder Article Text Treatment Fluoxetine plus cognitive behavioural therapy

2006 Evidence-Based Nursing